NCT07342309
Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United States
At risk: Primary completion moved at least 2 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 11 words
- Primary and study completion pushed from Oct 30, 2026 to Jan 29, 2027
- Secondary endpoints: details revised at 4 of 4 entries
- Minor Primary and study completion pushed from Jun 30, 2026 to Oct 30, 2026v4
- Minor Start date: Jan 3, 2026 to Sep 30, 2025v3
- Minor Trial status: Not Yet Recruiting to Active, Not Recruiting
- Start date changed from estimate of Jan 12, 2026 to Jan 3, 2026
- Site contact updated
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (4)
Arms and interventions
Adult patients (\>=18 years) with confirmed diagnosis of recurrent or de novo metastatic breast cancer (mBC) who were diagnosed between January 1, 2018, through March 31, 2024 (1 year prior to the data cutoff date, March 31, 2025) in the Flatiron Solid Tumor Discovery Clinico-Genomic Database (CGDB).
Patients meeting eligibility of the mBC cohort. Evidence of HER2 positive (HER2+) as defined by immunohistochemistry (IHC)/in situ hybridization (ISH) * IHC 3+ or * IHC 2+ and evidence of HER2 amplification by ISH or * ISH+ without further information on IHC.
Patients meeting eligibility of the mBC cohort. Evidence of NGS short variant alterations at any time in the database, regardless of the functional type, which includes missense, nonsense, frameshift, nonframeshift, or splice variants. Patients who are not included in the HER2+ subcohort.
Sites
1 site in 1 country
- RidgefieldRidgefield, Connecticut, United States